In English | En español
Questions About Cancer? 1-800-4-CANCER

Featured Clinical Trials

Highlighted NCI-Supported Cancer Studies < Back to Main

Page Options

  • Print This Page
  • Email This Document

Search Featured Trials

Related Pages

Colon and Rectal Cancer - Featured Clinical Trials

The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:

Treatment Based on Colorectal Tumor Protein Level
(Posted: 11/14/2006) - In this clinical trial, researchers will measure the level of a protein called thymidylate synthase (TS) in the tumors of patients with metastatic colorectal cancer and assign patients to one of two treatment groups based on their TS levels.

Monoclonal Antibodies for Metastatic Colorectal Cancer
(Posted: 09/19/2006) - In this trial, patients will receive one of two targeted agents, or a combination of the two, that were recently approved by the U.S. Food and Drug Administration for use with combination chemotherapy in the treatment of metastatic colorectal cancer.

Adjuvant Treatment of Rectal Cancer
(Posted: 05/16/2006) - In this trial, patients who were treated previously with neoadjuvant chemoradiotherapy (chemotherapy combined with radiation therapy) will be randomly assigned to receive adjuvant chemotherapy with or without the addition of the monoclonal antibody bevacizumab, which inhibits tumor blood vessel formation. Researchers will compare the overall survival of patients in the two treatment groups.

Neoadjuvant Therapy for Rectal Cancer
(Posted: 05/09/2006) - With this trial, researchers hope to improve neoadjuvant therapy for rectal cancer with the use of oral capecitabine and addition of oxaliplatin and, through the collection of tissue samples, learn how to identify those patients who will benefit from neoadjuvant therapy.

Adjuvant Therapy for Stage II Colon Cancer
(Posted: 03/14/2006) - In this trial, researchers are using molecular tests to help identify patients who are at high risk for recurrence after colon cancer surgery. High-risk patients will receive adjuvant chemotherapy (drug therapy given after surgery to help suppress cancer recurrence). Some of these patients will also receive bevacizumab. Low-risk patients will be observed but will not receive adjuvant therapy.

< Previous  1 2 3 4  Next >